Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited

10.47
USD
-0.11
(-1.04%)
4.13BMarket Cap
Mar 11Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
65.04
79.52
78.4
90.77
84.38
78.21
74.11
83.16
85.66
92.12
101.16
80
78.52
- -
Basic EPS, GAAP
11.04
11.45
9.47
11.29
13.3
14.23
10.27
10.58
14.4
11.83
9.97
-2.45
5.96
- -
Free Cash Flow per Basic Share
3.61
5.29
0.88
10.98
-2.67
5.33
18.19
15.03
11.92
12.49
14.09
11.68
15.47
- -
Dividend per Share
1.58
1.98
2.2
2.71
2.89
3.16
- -
- -
2.65
3.29
3.45
3.62
2.12
- -
Book Value per Share
63.66
75.11
93.71
93.38
108.78
119.55
152.73
144.93
160.26
195.12
192.01
192.18
182.94
182.94
Tangible Book Value per Share
-29.69
-25.18
-27.78
-51.98
-63.8
-37.28
-20.3
13.52
27.75
39.68
29.73
28.25
84.17
84.17
Basic Weighted Avg Shares
454
454
454
454
454
454
454
454
451
442
442
442
444
444
Sales/Revenue/Turnover
29,515
36,100
35,600
41,213
38,314
35,514
33,659
37,766
38,606
40,709
44,706
35,336
34,870
- -
Operating Margin (%)
25.16
23.27
28.65
23.66
25.74
24.3
24.08
21.51
22.77
20.26
23.37
14.13
13.27
- -
Depreciation Expense
824
1,000
1,200
1,267
1,372
1,274
1,603
1,653
1,713
1,788
1,973
2,089
2,231
- -
Net Income, GAAP
5,008
5,200
4,300
5,128
6,037
6,463
4,664
4,806
6,488
5,228
4,404
-1,083
2,647
- -
Effective Tax Rate (%)
21.25
20
29.51
17.98
16.64
28.54
19.49
19.89
20.24
20.24
22.93
- -
- -
- -
Profit Margin (%)
16.97
14.4
12.08
12.44
15.76
18.2
13.86
12.73
16.81
12.84
9.85
-3.06
7.59
- -
Working Capital
15,171
10,900
16,100
2,557
11,293
16,113
18,659
-4,046
11,166
21,352
19,784
21,206
25,055
25,055
LT Debt
29,916
25,500
32,700
28,978
46,725
39,713
36,019
266
10,582
21,375
25,141
31,508
9,496
9,496
Total Equity
28,876
34,100
42,500
42,391
49,375
54,213
69,217
65,627
70,942
86,236
84,861
84,893
80,370
80,370
Return on Invested Capital (%)
10.91
9.59
7.93
7.65
7.09
2.89
4.28
5.55
7.42
5.89
4.52
- -
- -
- -
Return on Capital (%)
11.49
9.74
7.19
7.82
7.94
7.69
5.61
5.71
7.73
6.02
5.17
- -
- -
- -
Return on Common Equity (%)
19.38
16.52
11.23
12.09
13.17
12.48
7.56
7.13
9.5
6.65
5.15
-1.28
3.2
- -

Capital Structure

ZAR

•

in mil. unless spec.
Jun'25
Dec'26
Jun'26
ST Debt
4,612
3,606
6,071
LT Borrowings
31,263
29,337
9,288
LT Finance Leases
245
- -
208
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
442
442
439
Market Capitalization
53,204
48,164
67,711

Working Capital

ZAR

•

in mil. unless spec.
Jun'25
Dec'26
Jun'26
Total Current Assets
38,702
57,330
41,280
Cash, Cash Equivalents & STI
6,409
5,620
15,998
Accounts Receivable, Net
10,646
10,069
8,748
Inventories
18,009
15,455
13,990
Total Current Liabilities
17,496
15,770
16,225
Payables & Accruals
- -
- -
- -
ST Debt
4,612
3,606
6,071
Deferred Revenue
- -
- -
- -

Growth Rates

ZAR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.13%
4.56%
-5.33%
Free Cash Flow
95.71%
2.05%
33.15%
Net Income, GAAP
-44.99%
-93.84%
-344.41%
Sales/Revenue/Turnover
0.36%
-0.96%
-1.32%
Total Cash Common Dividend
- -
- -
-41.22%

Semi-annual Revenue

ZAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
44,706
2025
- -
- -
35,336
2026
- -
- -
34,870

Semi-annual Earnings Per Share

ZAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
9.97
2025
- -
- -
-2.45
2026
- -
- -
5.96

Semi-annual Dividends Per Share

ZAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
3.45
2025
- -
- -
3.62
2026
- -
- -
2.12

Company Description

CEO
Stephen Bradley Saad
Full Time Employees
7,625
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Aspen Place Durban NL South Africa 2191
IPO Date
Dec 5, 1994
Business
Aspen Pharmacare Holdings Limited is a multinational pharmaceutical company focused on manufacturing and marketing post-patent branded medicines and generics for hospital and consumer markets; its core products and services encompass injectable pharmaceuticals including anaesthetics, anticoagulants, antithrombotics, analgesics and hormone replacements, alongside prescription and over-the-counter medicines in forms such as steriles, oral solids, liquids, semi-solids, biologicals and active pharmaceutical ingredients. The company operates 24 manufacturing facilities across 15 sites in more than 48 countries and territories, serving patients in over 115 countries with approvals from regulators including the US FDA, Australian TGA and European Directorate for the Quality of Medicines. Founded in 1997 and headquartered in Durban, South Africa (uMhlanga), Aspen maintains a presence in emerging and developed markets across Africa, Europe, the Middle East, Asia Pacific, the Americas and Australasia through subsidiaries like Aspen Global Incorporated and Aspen Oss BV. Recent strategic developments include advancing its generic semaglutide GLP-1 programme for type 2 diabetes and obesity treatment with production onboarding at sterile facilities in South Africa and France, alongside regulatory progress on Serum Institute paediatric vaccines for African markets and a long-term distribution agreement with Boehringer Ingelheim for its South African portfolio effective September 2025. In 2024, Aspen secured a €500 million loan from IFC, Proparco, DEG and DFC to bolster vaccine, insulin and essential medicine production and distribution in Africa, while pursuing organic growth in commercial pharmaceuticals including Mounjaro Kwikpen approval in South Africa. The company continues targeted product pipeline development, reshapes its China business via the Sandoz acquisition and anticipates mid-single-digit revenue growth with stronger EBITDA in FY2026.

Company News

  • Aspen Pharmacare wins approval for generic semaglutide in Brazil, South Africa

  • Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?

  • Are Medical Stocks Lagging Aspen Pharmacare (APNHY) This Year?

  • Aspen Pharmacare (OTCMKTS:APNHY) Shares Gap Down – Should You Sell?

  • Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?

  • Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?

  • Aspen sees Mounjaro Africa sales above $124 million in 2027

  • Aspen Pharmacare Holdings Limited (APNHY) Q4 2026 Earnings Call Transcript

  • Aspen Pharmacare Holdings Limited (APNHY) Shareholder/Analyst Call Prepared Remarks Transcript

  • Aspen Pharmacare Holdings Limited (APNHY) Q2 2026 Earnings Call Transcript

  • Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter

  • Aspen Pharmacare Holdings Limited (APNHY) Discusses Proposed Divestment of APAC Operations Excluding China Transcript

  • Aspen Pharmacare Holdings Limited (APNHY) Q4 2025 Earnings Call Transcript

  • Aspen Pharmacare Holdings Limited (APNHF) Q2 2025 Earnings Call Transcript

  • Aspen Pharmacare Holdings Limited (APNHF) Q4 2024 Earnings Call Transcript

  • Aspen Pharmacare Holdings Limited (APNHF) Q4 2023 Earnings Call Transcript

  • Aspen Pharmacare Holdings Limited (APNHF) Q4 2022 Earnings Call Transcript

  • New Strong Sell Stocks for July 11th

  • New Strong Sell Stocks for March 22nd

  • Aspen Pharmacare Holdings Limited (APNHF) CEO Stephen Saad on Interim 2022 Results - Earnings Call Transcript